In addition, high expression of ARSG, CD70, CTH, ERP29, FXN, NLE1, and PDK4 and low expression of BIRC3, ELL3, HIF1A, INHBA, MAEL, MEF2C, MMP9, PDK1, PRKCA, RARRES2, RRAGA, SNAP23, and UBQLN2 are associated with poorer outcomes in DLBCL patients. Here, MEF2C is linked to diffuse large B-cell lymphoma.